October 7, 2026 More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a…
October 7, 2026
More than 175 biotechs use pre-configured applications to streamline operations
PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics
. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effort, and cost.

"As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics. "Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance."
Biotechs are leveraging Veeva Basics to drive new ways of working, including shifting regulatory publishing strategies from outsourced to insourced. Veeva Submissions Publishing Basics
provides a modern application for submission building and health authority interactions that equips regulatory teams to bring publishing in-house. For biotechs preparing to publish their first submissions to the FDA, Veeva Basics enables them to hit critical regulatory milestones with improved visibility and control across the entire regulatory lifecycle.
"Insourcing our submission publishing through Veeva Basics gave us sharper quality control and significantly faster regulatory timelines," said Darryl Clarke, global head, regulatory operations at Structure Therapeutics. "We have modern applications with global support to execute quickly now, and the flexibility to scale in the future."
"Biotechs are responsible for so much of the innovation shaping the industry and they need technology that reflects the pace that they operate in," said Jim Thai, vice president, Veeva Basics. "It's been a privilege to work with industry pioneers and build this community of Veeva Basics customers advancing drug development."
Built on the proven Vault Platform
, Veeva Basics applications help customers to scale their technology infrastructure seamlessly as they grow. For more on Veeva Basics, visit veevabasics.com
, or register
for Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.
**About Veeva Systems
**Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation
, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com
.
**Veeva Forward-Looking Statements
**This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here
(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov
.
View original content to download multimedia:https://www.prnewswire.com/news-releases/emerging-biotechs-standardize-on-veeva-basics-to-accelerate-drug-development-302900615.html
SOURCE Veeva Systems
View All News
Investor Contact
[email protected]
[ (267) 460-5839](tel:(267) 460-5839)
Follow Us on Social

Quick Links
Email Alerts
Personal Information.
Email Address *Required Email Address is required. Email Address is invalid.
Investor Alert Options *
- News
- Quarterly Reports
- Annual Reports
- SEC Filings
- End of Day Stock Quote
- Events & Presentations
Investor Alert Options is required.
The captcha test has failed. Please try again.
Submit
Unsubscribe

© 2026 Veeva Systems Inc. - All rights reserved
5.191.0.1 (opens in new window)

Opt-Out Request Honored
Cookie Settings
When you visit our website, we store strictly necessary cookies on your browser. You cannot opt out of our use of strictly necessary cookies because these cookies are deployed in order to ensure the proper functioning of our website (such as allowing you to log into your account, redirecting you when you log out and remembering your input when you fill out a form.) Click below for more information about our use of strictly necessary cookies. For information about our privacy practices, please review our Privacy Notice below.
Privacy Notice
Allow All
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do, some parts of the site will not work. These cookies do not store any personally identifiable information.
Cookies Details
Functional Cookies
Functional Cookies
Always Inactive
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then these services may not function properly.
Cookies Details
Targeting Cookies
Targeting Cookies
Always Inactive
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookies Details
Back Button
Cookie List
Search Icon
Filter Icon
Clear
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Close
